AffinityImmuno

ELISA/assay

Natalizumab (Tysabri) Pharmacokinetic ELISA

EL-1611-141

1X96 wells

599.99美元

EL-1611-141

Natalizumab (Tysabri) Pharmacokinetic ELISA

酶联免疫吸附测定

599.99美元

479.99

美元

1X96 wells

-20C, 1 year

Natalizumab (Tysabri)

人类, 小鼠, 大鼠

50ng/毫升-1.56ng/毫升

1.5ng/毫升

The Natalizumab ELISA kit is designed to measure free Natalizumab with high specificity and sensitivity . This assay employs the sandwich enzyme immunoassay technique. A precoated anti-Natalizumab 96 well plate is provided. Calibrator, quality control samples and test samples are pipetted into the appropriate wells. Natalizumab present in biological matrices is bound by the immobilized capture antibody. After washing away any unbound substances, enzyme linked detection antibody is added to the wells. The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of Natalizumab present in test samples and the concentration is calculated from the standard series.

Coated microtiter plate, 96 wells Calibrator diluent. - 1.8ml Calibrator 12ul 10X wash buffer - 25ml Assay buffer - 50ml 1000X detection reagent - 17ul TMB - 12ml TMB stop solution - 12ml Plate sealers - 3

Direct sandwich ELISA

过氧化物酶 /OD450

Quantification of Natalizumab in biological matrices

Strip

血清血浆

15ul

2.5小时

Natalizumab

<10%, <10%

Natalizumab (Tysabri®) is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin used in the treatment of multiple sclerosis and Crohn's disease. Tysabri® and was previously named Antegren®. Natalizumab is administered by intravenous infusion every 28 days and reduces the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood– brain barrier.

This assay employs the sandwich enzyme immunoassay technique. Capture antibody is coated onto a 96 well microplate. Calibrator and test samples are pipetted into the appropriate wells. Natalizumab present in biological matrices is bound by the immobilized anti-Natalizumab antibody. After washing away any unbound substances, enzyme linked anti-Natalizumab antibody is added to the wells. The plate is washed to remove any unbound antibody-enzyme reagent and a substrate solution is added to the wells for color development. The color development is proportional to the amount of Natalizumab present in test samples. The color development is stopped and the intensity of the color is measured.

Prepare only the appropriate amount of required reagent on the day of use. Store all reagents as per instructions stated on the label. 1. Wash Buffer (1X) Preparation: Dilute wash buffer concentrate with ultra-pure water 1/10 before use (for example add 20mL concentrate to 180mL ultra-pure water). Mix well. 2. Detection Reagent (1X) Preparation: Dilute detection reagent with assay buffer 1/1000 before use (for example add 11μl concentrate to 11ml of assay buffer). Mix well. 3. Preparation of Calibrators: Prepare calibrators with concentrations ranging from 2500 ng/mL to 78 ng/mL. The following is an example calibrator curve.

1. Construct a standard curve by plotting the absorbance obtained from each standard against concentration. Use a 4 or 5 parameter curve fit. Alternatively a log-log curve fit may be used. 2. The concentration of the unknowns can be read directly from this standard curve using the absorbance value for each sample. 3. Any sample undiluted or diluted still reading greater than the highest standard should be diluted appropriately with assay buffer and retested. If the samples have been diluted, the concentration determined from the standard curve must be multiplied by the dilution factor.

This kit is compatible with EDTA-plasma, heparinplasma and serum samples. Samples can be stored at or below -20°C for up to 1 year.

Dilute calibrators and test samples 1/50 with assay buffer (for example add 5µL of prepared calibrator or sample to 245µL of assay buffer). Mix well. Do not store diluted samples.